900926:SSEShanghai Baosight Software Co., Ltd. Class B Analysis
Data as of 2026-07-22 - not real-time
$0.88
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its 20‑day, 50‑day and 200‑day simple moving averages, signaling a clear bearish price positioning. RSI sits just under the neutral 50‑point level, suggesting limited upside momentum in the short run. The MACD histogram is modestly positive, offering a faint bullish signal that is not yet strong enough to reverse the prevailing trend. Volume is on a decreasing trajectory, which reinforces the weakening buying pressure. Beta is very low, indicating the share is relatively insulated from broader market swings, yet 30‑day price volatility remains elevated, reflecting a choppy price environment. Overall, the technical picture is bearish but the low beta and modest bullish MACD hint at a potential bottom forming.
Fundamentally, the DCF model points to a fair value more than double the current price, implying substantial upside potential. The forward PE is markedly lower than the trailing PE, highlighting expected earnings acceleration. Dividend yield is high relative to peers, though the payout ratio exceeds 100%, raising questions about sustainability. Revenue growth is modest, but profit margins sit in the low‑double‑digit range, and cash generation is solid with low leverage. The balance sheet is strong, featuring ample cash and a low debt‑to‑equity ratio. These fundamentals, combined with the attractive valuation gap, suggest the stock is undervalued and could reward patient investors.
Fundamentally, the DCF model points to a fair value more than double the current price, implying substantial upside potential. The forward PE is markedly lower than the trailing PE, highlighting expected earnings acceleration. Dividend yield is high relative to peers, though the payout ratio exceeds 100%, raising questions about sustainability. Revenue growth is modest, but profit margins sit in the low‑double‑digit range, and cash generation is solid with low leverage. The balance sheet is strong, featuring ample cash and a low debt‑to‑equity ratio. These fundamentals, combined with the attractive valuation gap, suggest the stock is undervalued and could reward patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price remains below key moving averages
- Decreasing volume indicating weakening momentum
- Bearish trend direction despite a faint bullish MACD
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF valuation shows more than 100% upside
- Low forward PE suggests earnings acceleration
- Strong cash position and attractive dividend yield
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Industry tailwinds for digitalization in manufacturing
- Solid ROE and consistent free cash flow generation
- Significant margin of safety versus fair value
Key Metrics & Analysis
Financial Health
Revenue Growth4.20%
Profit Margin11.21%
P/E Ratio14.7
ROE10.18%
ROA3.48%
Debt/Equity14.16
P/B Ratio1.5
Op. Cash Flow$2.2B
Free Cash Flow$576.3M
Industry P/E33.9
Technical Analysis
TrendBearish
RSI47.9
Support$0.80
Resistance$0.92
MA 20$0.87
MA 50$0.90
MA 200$1.01
MACDBullish
VolumeDecreasing
Fear & Greed Index91.21
Valuation
Fair Value$4.04
Target Price$1.87
Upside/Downside112.95%
GradeUndervalued
TypeBlend
Dividend Yield3.78%
Risk Assessment
Beta0.25
Volatility37.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.